Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML
Lucid Diligence Brief: Cantargia nadunolimab in MDS and AML Professional…
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for TCR-mimetics
Lucid Diligence Brief: Crossbow Therapeutics $77 million Series B for…
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics
Lucid Diligence Brief: Amgen acquires Dark Blue Therapeutics Professional…
Hematology Today—November 3, 2025
Catch the latest hematology news, featuring industry updates, clinical…
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics
Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics Professional…
AI in Healthcare and Digital Health Video Recap — October 20, 2025
This biweekly video summary highlights global updates in AI in Healthcare and…
Hematology Today: CAR-T, Gene Therapy and Radioconjugates (Oct 6–13, 2025)
This week’s hematology update highlights groundbreaking CAR-T and gene therapy…
Hematology Weekly News - October 6th 2025
Hematology Update: Cemsidomide–Elranatamab Combo, Ziftomenib AML Trial, Fast…
Hematology Weekly News - September 22nd 2025
Hematology Update: Inobrodib Trial, Tecvayli Combo, Bexobrutideg Data and……
Rare Diseases Weekly News - September 18th 2025
🧬 This Week in Rare Diseases: Positive DMD Results, FDA Approves Selumetinib…
Hematology Weekly News - September 15th 2025
Hematology Update: Jaypirca CLL win, BTK degrader data, WHO EML update and…
Hematology Weekly News - September 8th 2025
🔬🩸 Hematology Updates: Functional Cure Signals, Head-to-Head CAR-T, Outpatient…